ACC president points to the continued importance of studying coronary inflammation

 

Coronary inflammation is emerging as an important target in the prevention and treatment of cardiovascular disease, with growing evidence linking inflammatory processes to cardiovascular outcomes. New therapies and imaging technologies may offer opportunities to better identify and address this residual risk, American College of Cardiology (ACC) President Roxana Mehran, MD, told Cardiovascular Business.

Mehran, professor of medicine at the Icahn School of Medicine at Mount Sinai, delivered a keynote presentation on coronary inflammation at TCT 2026 in San Diego. She discussed the growing understanding of inflammation's role in atherosclerosis, new ways to detect it and the potential for state-of-the-art therapies.

For years, inflammation was viewed as a possible variable in cardiovascular disease. However, Mehran said accumulating evidence now shows a strong association between cardiovascular inflammation and plaque rupture.

"I talked a lot about inflammation at this meeting and how inflammation is playing a very important role," Mehran explained. "It used to be just be a confounder, but actually, there's so much data now that is correlating cardiovascular inflammation to cardiovascular events. And the way we know about it is elevated C-reactive protein (CRP), and now we have imaging that tells us peri-adventicial fat and fat attenuation indices (FAI) could be looked at as a marker of inflammation along with CRP. The whole idea is, if we catch it early enough, we can reverse some of those negative impacts from inflammation."

Subscribe to Cardiovascular Business News

Elevated CRP is a systemic measure of inflammation. But FAI CT imaging now makes the visualization of coronary artery inflammation possible. FAI can be used to identify inflamed arteries that can help clinicians flag which patients may benefit from drug therapy. It can also track the regression of inflammation after treatment.

The cardiology community's interest in inflammation has accelerated following the 2023 U.S. Food and Drug Administration approval of low-dose colchicine for reducing cardiovascular risk in certain patients. As Mehran noted, however, there are side effects from the drug, so a risk coronary assessment that shows clear additional heart attack risk can help better identify which patients would benefit.

Following an acute coronary syndrome (ACS), for example, patients experience an initial inflammatory response associated with plaque rupture followed by chronic inflammation that can persist after the acute event. She said the ARTEMIS trial is among the studies investigating this area.

She also pointed to the ZEUS trial, which evaluated ziltivekimab, an interleukin-6 (IL-6) inhibitor, in patients with chronic kidney disease and elevated CRP. The trial's results were neutral, raising questions about patient selection, timing and how inflammatory therapies should be incorporated into cardiovascular prevention strategies.

Read more about the ZEUS trial results presented at AHA 2026.

But Mehran said the neutral findings should not discourage researchers from performing additional investigations of inflammation as a treatment target. Instead, she suggested that future studies may need to examine whether starting therapy earlier or combining it with aggressive lipid lowering could produce better results.

Safety also remains a critical consideration. Targeting inflammatory cytokines can have significant side effects, meaning therapies must demonstrate both safety and meaningful long-term clinical benefits.

She noted that several existing cardiovascular therapies already have anti-inflammatory effects in addition to their lipid-lowering or metabolic benefits. High-intensity statin therapy, for example, has demonstrated benefits related to inflammation, while GLP-1 receptor agonists also have been associated with reductions in inflammatory activity.

The JUPITER trial, published in 2008, helped establish the importance of targeting patients with elevated CRP, demonstrating cardiovascular benefits from rosuvastatin in people with elevated inflammatory markers despite relatively low LDL cholesterol.

Mehran also discussed the CANTOS trial, which demonstrated that targeting interleukin-1 beta (IL-1β) could reduce recurrent cardiovascular events independently of lipid lowering. However, safety concerns, including an increased risk of fatal infections, limited the potential for widespread clinical adoption.

Researchers are also investigating whether inflammation can be addressed further upstream in the inflammatory cascade, including targeting the NLRP3 inflammasome, or through more specific pathways such as IL-1β and IL-6 inhibition.

Mehran said future studies should evaluate more than short-term reductions in cardiovascular events. Researchers also need to determine whether these treatments produce lasting changes in plaque composition, imaging markers such as FAI and the overall progression of atherosclerosis.

"We're in an age of transformation" in how clinicians think about plaque regression and early prevention, Mehran said.

Dave Fornell is a digital editor with Cardiovascular Business and Radiology Business magazines. He has been covering healthcare for more than 16 years.

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: [email protected]

Subscribe to Cardiovascular Business News

Subscribe to Cardiovascular Business News